ClinicalTrials.gg
CompletedNCT00481312MIDEXUpdated May 7, 2012

Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)

A Phase 3 interventional study of Dexmedetomidine and Midazolam in Continuous Sedation in Initially Sedated Adults in ICU, sponsored by Orion Corporation, Orion Pharma. Completed at 43 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-07.

Sponsored by Orion Corporation, Orion Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
501
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients in ICU who need help with their breathing are put onto a machine called a ventilator and are also given a medicine, called a sedative, which helps them to sleep and makes them more comfortable. Midazolam is a sedative that is routinely used for these purposes.

For most patients the aim of sedation is to make them sleepy but still able to respond to nursing staff (light sedation)

Dexmedetomidine is a new sedative for use in intensive care and in this clinical study, dexmedetomidine is compared to midazolam. It is thought that dexmedetomidine might be slightly better at allowing patients to be sleepy but still respond to people around them. It also does not appear to affect patient's breathing. the purpose of this study is to test whether dexmedetomidine really does have these advantages compared to midazolam.

in this study we hope to show that: dexmedetomidine is at least as good as midazolam in helping patients to sleep better and making them more comfortable, and that they are able to co-operate better with the staff treating them, and that patients treated with dexmedetomidine require a shorter time on the ventilator than those treated with midazolam.

Read the detailed description

This is a phase III, multi-centre, prospective, randomised, double-blind, double-dummy, active comparator study. The study consists of three periods: screening, double-dummy treatment and follow-up period.

All patients admitted to ICU will be pre-screened according to inclusion and exclusion criteria prior to informed consent using available clinical data.

Informed consent, screening and randomisation procedures should be completed within 72 hours from the time of admission to ICU and within 48 hours from starting continuous sedation. Eligible study subjects requiring light to moderate sedation (Richmond Agitation-Sedation Scale [RASS] = 0 to -3) will be randomised to either continue on midazolam or switch to dexmedetomidine. Patients should not have received any other continuously or regularly administered sedative agent than midazolam infusion during the last 12 hours except for opioid analgesics. Study treatments will be titrated to achieve an individually targeted sedation range determined on a daily basis. Rescue treatment (i.e. propofol boli) may be given if needed to achieve the target depth of sedation. Continued need for sedation will be assessed at a daily sedation stop, conducted at the same time each day. First sedation stop may be 12-36 hours from randomisation, depending on the time of day the study subject is randomised. The duration of study treatment is limited to a maximum of 14 days from randomisation. Following withdrawal of sedation, study subjects will be monitored for 48 hours and contacted by telephone 31 and 45 days after randomisation.

02

Conditions studied

  • Continuous Sedation in Initially Sedated Adults in ICU

Keywords

  • Initial Sedation
  • Mechanical ventilation
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and over
  • Clinical need for sedation of an initially intubated (or tracheotomised) and ventilated (with inspiratory assistance) patient
  • Prescribed light to moderate sedation (target RASS = 0 to -3) using midazolam infusion
  • Patients should be randomised within 72 hours from ICU admission and within 48 hours of commencing continuous sedation in the ICU
  • Patients should have an expected requirement for sedation of at least 24 hours from time of randomisation
  • Written must be obtained according to local regulations before starting any study procedures other than pre-screening.

Exclusion criteria

Exclusion Criteria:

  • Acute severe intracranial or spinal neurological disorder due to vascular causes, infection, intracranial expansion or injury
  • Uncompensated acute circulatory failure at time of randomisation (severe hypotension with MAP \< 55 mmHg despite volume and pressors)
  • Severe bradycardia (HR \< 50 beats/min)
  • AV-conduction block II-III (unless pacemaker installed)
  • Severe hepatic impairment ( > 101 µmol/L)
  • Need for muscle relaxation at the time of randomisation (may only be used for intubation and initial stabilization)
  • Loss of hearing or vision, or any other condition which would significantly interfere with the collection of study data
  • Burn injuries requiring regular anaesthesia or surgery
  • Use of centrally acting α2 agonists or antagonists at the time of randomisation, notably clonidine (see section 5.7 for prior and concomitant treatments)
  • Known allergy to any of the study drugs or any of the study drugs
  • Patients who have or are expected to have treatment withdrawn or withheld due to poor prognosis
  • Patients receiving sedation for therapeutic indications rather than to tolerate the ventilator (e.g. epilepsy)
  • Patients unlikely to require continuous sedation during mechanical ventilation (e.g. Guillain-Barré syndrome)
  • Patients who are unlikely to be weaned from mechanical ventilation; e.g. diseases/injuries primarily affecting the neuromuscular function of the respiratory apparatus such as clearly irreversible disease requiring prolonged ventilatory support (e.g. high spinal cord injury or advanced amyotrophic lateral sclerosis)
  • Distal paraplegia
  • Positive pregnancy test or currently lactating
  • Received any drug within the preceding 30 days
  • Concurrent participation in any other interventional study (any study in which patients are allocated to different treatment groups and/or non-routine diagnostic or monitoring procedures are performed)
  • Previous participation in this study
  • Any other condition which, in the investigator's opinion, would make it detrimental for the subject to participate in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
501 participants (actual)

Study arms

  • Active comparator
    1

    Dexmedetomidine

    Drug: Dexmedetomidine

  • Active comparator
    2

    Midazolam

    Drug: Midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required

    Time frame: RASS score will be assessed approximately 2 hourly during the treatment period and during the 48-hour follow-up period

  2. Duration of mechanical ventilation the number of days the patient receives mechanical ventilation will be recorded

    Time frame: This variable will be dependent on the individual patient and the number of days they require mechanical ventilation .

Secondary outcomes

  1. Nurse's assessment of subject communication with visual analogue scales (VAS)Patients rousability and ability to co-operate and communicate will be measured using a visual analogue scale.

    Time frame: This will be measured at the end of every nursing shift whilst the patient remains on study treatment (maximum 14 days)

  2. Length of ICU stay

    Time frame: Number of days a patient is in ICU which will vary depending on the underlying illness of the patient

07

Study locations

43 sites
  • ULB Erasme, Route de Lennik
    Brussels, 1070, Belgium
  • UZ Brussel, Intensive Care Dept. Laarbeeklaan 101
    Brussels, 1090, Belgium
  • Universitaer Ziekenhuis Gent, Intensieve Zorgen, De Pintelaan 185
    Gent, 9000, Belgium
  • CHU de Liege (Sart Tilman), Domaine de Sart-Tilman
    Liege, 3000, Belgium
  • East Tallinn Central Hospital, Ravi Stret 18
    Tallinn, 10138, Estonia
  • North Estonian Regional Hospital, Centre of Intensive Care, J. Sutiste Tee 18
    Tallinn, 13419, Estonia
  • North Estonian Regional Hospital, Dept. of Postoperative Intensive Care, J. Sutiste Tee 18
    Tallinn, 13419, Estonia
  • Tartu University Hospistal, Clinic of Anesthesiology and Intensive Care, L. Puusepa 8
    Tartu, 51014, Estonia
  • Oulu University Hospital, Kajaanintie 50
    Oulu, 90029 OYS, Finland
  • Tampere University Hospital, ICU
    Tampere, 33521, Finland
  • Centre Hospitalier Universitaire d'Angers, Reanimation medicale est de Mededicne Hyperbare, 4 Rue Larrey
    Angers cedex 9, 49933, France
  • Centre Hospitalier Victor Dupouy Hopital Dupuytren, Service Reanimation Polyvalente, 69, Rue du Lt Colonel Prud'hon
    Argenteuil, 95107, France
  • Centre Hospitalier Universitaire de Grenoble, Service de Reanimation Medicale, Boulevard de la Chantourne, BP 217
    Grenoble cedex 09, 38043, France
  • Centre Hospitalier La Roche sur Yon CHD les Oudaireis, Service Reanimation CHD la Roche sur Yon, Les Oudairies
    La Roche sur Yon Cedex, 85925, France
  • Hopital Albert Calmette, Boulevard Du Pr. Jules Leclercq
    Lille, 59037, France
  • Centre Hospitalier Universitaire Limoges Hopital Dupuytren, Service de Reanimation Polyvalente, 2, Avenue Martin Luther King
    Limoges, 87042, France
  • Centre Hospitalier Universitaire d'Orleans, Reanimation Medicale, 1, rue Prote Madeleine, BP 2439
    Orleans cedex 1, 45032, France
  • Hopital Bichat-Claude, Dept. D'Anasehesie et Reanimation Chirurgicale, 46, rue Henri-Huchard
    Paris, 75018, France
  • Groupe Hospitalier Cochin Saint Vincent de Paul, Service de Reanimation Medicale, 27 Rue du Faubourg Saint Jacques
    Paris, 75679, France
  • Hopital Foch, Service Renimation, 40 Rue Worth, Suresnes Hauts de Seine
    Paris, 92150, France
  • Centre Hospitalier Universitaire de Poitiers, Reanimation Medicale, 2, Rue de la Miletrie
    Poitiers, 86021, France
  • Centre Hospitalier Regional et Universitaire - Hopital Bretonneau Service Reanimation Medicale Polyvalente, 2, Boulevard Tonnelle, Tours cedex 9
    Tours, 37044, France
  • Universitatsklinikum Bonn, Klinik u. Poliklinik f. Anasthesiologie u. Operative Intensivmedizin, Sigmund-Freud-Strasse 25
    Bonn, 53105, Germany
  • Universitatsklinikum Greifswald, Klinik u. Poliklinik f. Anasthesiologie u. Intensivmedizin, Friedrich-Loeffler-Str. 23b
    Greifswald, 17475, Germany
  • Universitatsklinikum Tubingen, Klinik fur Anasthesiologie und Intensivmedizin, Hoppe-Seyler-Strasse 3
    Tubingen, 72076, Germany
  • VU Medisch Centrum, De Boelelaan 1117
    Amsterdam, 1081 HV, Netherlands
  • Gelre Hospitals - Locatie Lucas, A.Schweitzerlaan 32
    Apeldoorn, 7334 DZ, Netherlands
  • Amphia Ziekenhuis, Dept. Intensieve Zorgen, Molengracht 21
    Breda, 4818, Netherlands
  • Albert Schweitzer Hospital, Locatie Dordwikj, Albert Schweitzerplaats 25
    Dordrecht, 3318 AT, Netherlands
  • Kennemer Hospital, Boeerhaavelaan 29
    Haarlem, 2035 RC, Netherlands
  • Saint Elisabeth Ziekenhuis, Dept. Intensieve Zorgen, Hilvarenbeekseweg 60
    Tilburg, 5022 GC, Netherlands
  • Viecuri MC voor Noord-Limburg, Locatie Venlo, Dept. Intensieve Zorgen, Tegelseweg 210
    Venlo, 5912 BL, Netherlands
  • Isala Klinieken, Locatie Weezenlanden, Groot Wezenland 20
    Zwolle, 8011 JW, Netherlands
  • Haukeland University Hospital, Intensive Care Unit, Jonas Liesvei 65
    Bergen, 5021, Norway
  • Rikshospitalet, Universitetsklinikk, Sognsvannsveien 20
    Oslo, 0027, Norway
  • Ulleval University Hospital, Medical and Surgical ICU, Kirkeveien 166
    Oslo, 0450, Norway
  • Aker Universtetssykehus HF, Anestesiavdelingen, Trondheimsveien 235
    Oslo, 0514, Norway
  • Inselspital, Freiburgstrasse 4
    Bern, CH-3010, Switzerland
  • Kantonsspital Winterthur, Brauerstrasse 15,
    Winterthur, 8401, Switzerland
  • Universitatsspital Zurich, Klinik fur Innere Medizin, Intensivstation, Ramistrasse 100
    Zurich, 8091, Switzerland
  • University Hospital Birmingham, Department of Anaesthesia, Queen Elizabeth Hospital,
    Birmingham, B15 2TH, United Kingdom
  • Birmingham Heartlands Hospital, Bordesely Green East
    Birmingham, B9 5SS, United Kingdom
  • Derriford Hospital, Dept. of Intensive Care Level 4, Derriford Road
    Plymouth, PL6 8DH, United Kingdom
08

References and documents

Publications

  • Turunen H, Jakob SM, Ruokonen E, Kaukonen KM, Sarapohja T, Apajasalo M, Takala J. Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation. Crit Care. 2015 Feb 19;19(1):67. doi: 10.1186/s13054-015-0787-y. PubMed 25887576 ↗
  • Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, Bratty JR, Takala J; Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012 Mar 21;307(11):1151-60. doi: 10.1001/jama.2012.304. PubMed 22436955 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Aug 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2007
First posted
Jun 1, 2007
Start
Jun 2007
Primary completionActual
Aug 2009
CompletionActual
Oct 2009
Last update
May 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00481312
Responsible party
Sponsor
First posted
Jun 1, 2007
Start date
Jun 2007
Primary completion
Aug 2009
Completion
Oct 2009
Last update
May 7, 2012

Study contacts

Stephan Jakob, MD PhD
principal investigator · Insel Spital, Bern CH-3010 Switzerland
Angela Ruck, BSc PhD
study director · Orion Pharma R&D Nottingham England

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Midazolam

Start the discussion